AI Science Tracker
EN

Survival forests associate clinical and treatment-plan features with glioma survival

Zhejiang University · 24 Mar 2021 · medicine

Discovery

Survival forests associate clinical and treatment-plan features with glioma survival

Source check: Source checked. Not independent scientific confirmation.

Finding: A retrospective 95-patient high-grade glioma study used random survival forests to relate clinical characteristics and radiotherapy dose-volume features to observed survival. Age, tumor volume, grade, performance status, IDH status and a dose-coverage feature were selected by the learned model. This is an exploratory cohort association; the study does not establish that changing radiation dose improves survival or that its prediction performance generalizes to new hospitals.

Technology: Random survival forest; support-vector-machine comparison

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The survival forest learns nonlinear relationships between clinical/dose-volume features and survival, selecting a multifeature risk representation for retrospective outcome analysis.
Test and result
The source analyzes 95 historical patients, randomly dividing 57 for model development and 38 for testing. The survival forest selects clinical factors and a treatment-plan dose-coverage feature associated with recorded outcomes.
Limitation / still unknown
Continuous variables were converted using outcome-optimized cut points before the described split; preprocessing isolation is not established, so reported test accuracy may be optimistic. Feature selection and small-cohort risk thresholds need validation. Treatment choices, tumor size and case mix can confound dose–survival relationships. Decision-curve analysis is model-based, not demonstrated clinical utility, and no causal dose-prescription guidance follows.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC8026951/unicode

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Exact primary BioC document ID and article-front DOI/title/PMID; clinical/statistical model Methods and survival Results/limitations. Current primary notice metadata checked; treatment instructions are not represented..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.